Back to Search
Start Over
supplementary table from A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Table 1. Best response to treatment among response-evaluable patients treated with RPIID (n = 43)
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....230388bc3050804de01dea976cf8fbc0
- Full Text :
- https://doi.org/10.1158/1078-0432.22456421.v1